Russia registered its first candidate vaccine, developed through the Gamaleya Institute in Moscow, in August. The Sputnik-V advanced-stage trials, which are expected to involve 40,000 participants, were introduced on 26 August.
The Russian Direct Investment Fund (DRIF), the sovereign state fund developing the vaccine, signed its first export agreement with Kazakhstan in August.
Kazakhstan is about to buy more than 2 million doses at first and may later increase the volume to five million doses, the RDIF said at the time.
The agreement with Mexico is expected to be announced later on Wednesday, he said.